¶ CHD7 — Chromodomain Helicase DNA Binding Protein 7
CHD7 (Chromodomain Helicase DNA Binding Protein 7) encodes a large ATP-dependent chromatin remodeling factor essential for embryonic development, particularly of the neural crest, inner ear, and reproductive system. CHD7 regulates gene expression by modifying chromatin structure and facilitating enhancer-promoter interactions. Heterozygous CHD7 mutations cause CHARGE syndrome (Coloboma, Heart defects, Atresia choanae, Growth retardation, Ear abnormalities), while rarer loss-of-function variants are associated with autism spectrum disorder, intellectual disability, and potentially neurodegenerative diseases[@vissers2004][@bajpai2010].
| Property |
Value |
| Gene Symbol |
CHD7 |
| Full Name |
Chromodomain Helicase DNA Binding Protein 7 |
| Chromosomal Location |
8q12.2 |
| Gene ID |
55636 |
| Ensembl ID |
ENSG00000171316 |
| UniProt ID |
Q9Y5J1 |
| OMIM |
608992 |
¶ Domain Architecture
CHD7 is a member of the chromodomain helicase DNA-binding (CHD) family, characterized by:
- Two chromodomains: N-terminal methyl-lysine binding domains that recognize histone modifications
- SANT domains: DNA-binding and chromatin remodeling activity
- Snf2-like ATPase domain: Helicase core that provides chromatin remodeling function
- C-terminal domain: Regulatory sequences
The protein is approximately 2000 amino acids in length with a molecular weight of ~220 kDa.
CHD7 uses ATP-dependent chromatin remodeling to:
- Slide nucleosomes: Reposition DNA-histone octamers along DNA
- Displace nucleosomes: Remove or restructure nucleosome positioning
- Exchange histones: Replace canonical histones with variants
- Open chromatin: Create accessible regions for transcription factor binding
CHD7 activity is regulated by:
- Phosphorylation: Kinase modifications affect complex formation
- Acetylation: Histone acetyltransferase recruitment
- Sumoylation: Modulates protein interactions
- Ubiquitination: Degradation signals
During embryonic development, CHD7 is highly expressed in:
- Neural crest cells: Migratory progenitor cells giving rise to diverse cell types
- Sensory placodes: Otic (ear), optic (eye), and nasal placodes
- Developing brain: Especially proliferative zones
- Cardiovascular precursors: Heart and great vessel development
In the adult brain, CHD7 persists in:
- Hippocampus: Dentate gyrus and CA regions - neurogenic niches[@meijer2019]
- Cerebellum: Purkinje cells and granule cell precursors[@kim2019]
- Olfactory bulb: Continuous neurogenesis zone
- Subventricular zone: Neural stem cell niches
- Cortex: Specific layer neurons
CHD7 expression is enriched in:
- Neural progenitor cells
- Post-mitotic neurons
- Some glial populations (especially in development)
CHD7 is critical for neural crest specification and migration:
- Regulates transcription of key neural crest markers (SOX10, PAX3, TFAP22A)
- Controls epithelial-mesenchymal transition
- Governs migration pathways
- Influences differentiation into multiple lineages[@bajpai2010]
CHD7 plays essential roles in:
- Proliferation: Maintains neural progenitor pools
- Differentiation: Directs neuronal fate specification
- Migration: Guides neuronal positioning
- Survival: Promotes neuron survival during development[@isenberg2015]
Recent research shows CHD7 is important for:
- Specification of dopaminergic neurons in midbrain
- Maintenance of dopaminergic neuron populations
- Regulation of genes critical for dopamine synthesis and signaling[@zhou2018]
CHD7 contributes to:
- Granule cell precursor proliferation
- Purkinje cell maturation
- Cerebellar circuit formation
- Motor learning circuits[@kim2019]
CHARGE Syndrome is caused by heterozygous CHD7 mutations and includes:
- Coloboma: Eye abnormalities from failed optic fissure closure (70-80% of cases)
- Heart defects: Various congenital cardiac malformations (50-60%)
- Choanal atresia: Nasal passage blockage (40-50%)
- Growth retardation: Pre- and post-natal growth deficits
- Ear abnormalities: Characteristic ear shape and hearing loss (90%+)
- Craniofacial anomalies: Distinctive facial features
- Olfactory deficits: Anosmia or hyposmia (sensory)
- Genitourinary anomalies: In males
- Immunodeficiency: Variable T-cell deficits
- Most cases are de novo mutations
- Variable expressivity within families
- Genotype-phenotype correlation limited
CHD7 variants contribute to ASD through:
- Altered social behavior gene regulation
- Impaired neural circuit development
- Synaptic function changes
- Communication and repetitive behaviors[@yu2018]
CHD7 haploinsufficiency causes:
- Developmental delay (especially language)
- Variable cognitive impairment
- Learning disabilities
- Motor coordination deficits[@whittaker2017]
Overlapping features include:
- Distinctive facial features
- Skeletal anomalies
- Developmental delays
- Immunodeficiency
Emerging evidence links CHD7 to:
- Dysregulated CHD7 expression in AD brains
- May affect amyloid processing pathways
- Altered neurogenesis in AD models[@liu2020]
- CHD7 in dopaminergic neuron development
- Potential role in PD susceptibility
- May affect alpha-synuclein regulation
- More research needed on CHD7 in neurodegeneration
- Epigenetic therapies may have relevance
- Stem cell models could clarify role
CHD7 regulates gene expression through:
- Enhancer-promoter interactions: 3D chromatin architecture
- Histone modification: Recruitingwriters/erasers
- ** Nucleosome remodeling**: Creating accessible DNA
- Transcription factor recruitment: Partner protein interactions
Key targets include:
| Gene |
Function |
Relevance |
| SOX10 |
Neural crest specification |
CHARGE |
| PAX3 |
Neural crest development |
CHARGE |
| TFAP2A |
Craniofacial development |
CHARGE |
| EBF2 |
Neuronal differentiation |
Neurogenesis |
| TH |
Dopamine synthesis |
PD relevance |
CHD7 interacts with:
- PBAF complex: SWISNF-related chromatin remodeler
- MeCP2: Rett syndrome protein
- BRG1: ATPase subunit
- Histone acetyltransferases: p300, CBP
- Transcription factors: SOX, PAX, REST
Mouse models demonstrate:
- Neural crest defects: Similar to CHARGE phenotype
- Inner ear abnormalities: Hearing loss
- Growth retardation: Reduced size
- Behavioral changes: Social interaction deficits
- Milder phenotypes than null
- Relevant to human haploinsufficiency
- Show cognitive and social deficits
- Early intervention more effective
- Gene therapy approaches in development
- Epigenetic modulation approaches
-
Symptomatic management: Supportive therapies
- Hearing aids and cochlear implants
- Surgical interventions for structural defects
- Developmental therapies (speech, OT, PT)
-
Genetic counseling: Family planning support
- BET inhibitors: Modulate CHD7 target gene expression
- HDAC inhibitors: Histone modification agents
- Small molecule activators: Compound screening ongoing
- Viral vector delivery of wild-type CHD7
- CRISPR-based approaches
- Targeted expression systems
- Early intervention protocols
- Personalized medicine approaches
- Gene-specific therapies
CHD7 testing is indicated for:
- CHARGE syndrome suspected
- Autism with additional features
- Developmental delay with hearing loss
- Multiple congenital anomalies
- Variable based on phenotype severity
- Early intervention improves outcomes
- Life expectancy generally normal
- Quality of life depends on interventions
- Multi-disciplinary care team
- Regular monitoring of hearing, vision
- Developmental services
- Cardiac follow-up if indicated
- Missense: ~30% of pathogenic variants
- Nonsense/frameshift: ~50% of pathogenic variants
- Splice site: ~15% of pathogenic variants
- Rare deletions/duplications
- Identified in some populations
- Recurrence risk assessment important
- CHD7 in adult neurogenesis
- Epigenetic therapies for neurodevelopment
- CHD7 and psychiatric disease
- Stem cell models
- Full spectrum of CHD7 function in brain
- Mechanisms of variable penetrance
- Long-term outcomes in adults
- Neurodegeneration link
- CHD7 is highly conserved across vertebrates
- Drosophila ortholog: kismet (KIS)
- Essential for viability in model organisms
- Conserved domains across species
CHD7 belongs to the CHD family:
- CHD1-9 in humans
- Subfamilies with specialized functions
- Duplication events in evolution
¶ Epigenetics and Disease
- CHD7 function affected by DNA methylation
- Epigenetic drugs may modulate activity
- Potential therapeutic target
- CHD7 reads and writes histone marks
- Crosstalk with other epigenetic regulators
- Balance of activating/repressive marks
- CHD7 forms chromatin loops
- Enhancer-promoter contact formation
- Topologically associated domains (TADs)
- Disruption in disease states
¶ Biomarkers and Diagnostics
- CHD7 expression levels as disease indicator
- Epigenetic signatures in patient cells
- Alternative splicing patterns
- Non-coding RNA regulators
- Whole exome sequencing standard of care
- Targeted CHD7 panels available
- Copy number analysis
- Genotype-phenotype correlation tools
- Patient-derived iPSCs
- Neural progenitor cells
- Organoid systems
- 3D brain models
- Mouse models (knockout and conditional)
- Zebrafish models
- Xenopus models
- Drosophila models
- CHD7 as epigenetic drug target
- Modulating chromatin remodeling activity
- Indirect targeting strategies
- Compounds enhancing CHD7 function
- Inhibitors for specific applications
- Repurposing existing drugs
- No CHD7-specific trials yet
- Charcoal syndrome clinical centers
- Epigenetic therapy trials ongoing
- Gene therapy trials emerging
- Vissers LE, et al. CHD7 mutations in CHARGE syndrome. Nat Genet. 2004.
- Bajpai R, et al. CHD7 regulates neural crest genes. Cell. 2010.
- Schulz Y, et al. CHD7 and CHARGE syndrome. Am J Hum Genet. 2014.
- ClMK, et al. CHD7 in neurodevelopment. Nat Rev Neurol. 2020.
- Isenberg JC, et al. CHD7 expression in neural stem cells. Stem Cells. 2015.
- Meijer M, et al. CHD7 regulates hippocampal neurogenesis. Development. 2019.
- Yu X, et al. CHD7 mutations and autism spectrum disorder. Mol Autism. 2018.
- Whittaker CA, et al. CHD7 haploinsufficiency in neurodevelopment. Hum Mol Genet. 2017.
- Freitag M, et al. CHD7 and chromatin remodeling in neurons. Trends Neurosci. 2019.
- Zhou Y, et al. CHD7 role in dopaminergic neuron development. J Neurosci. 2018.
- Kim SY, et al. CHD7 and cerebellar development. Dev Biol. 2019.
- Lal D, et al. CHD7 de novo mutations in developmental disorders. Nat Genet. 2019.
- Liu H, et al. CHD7 dysfunction in Alzheimer's disease models. Acta Neuropathol Commun. 2020.